Abstract:Carbon monoxide (CO)-based gas therapy has emerged as an attractive therapeutic strategy for cancer therapy. However, the main challenges are the in situ-triggered and efficient delivery of CO in tumors, which limit its further clinical application. Herein, we developed an erythrocyte membrane-biomimetic gas nanofactory (MGP@RBC) to amplify the in situ generation of CO for combined energy starvation of cancer cells and gas therapy. This nanofactory was constructed by encapsulating glucose oxidase (GOx) and Mn2(CO)10 (CO-donor) into the biocompatible polymer poly(lactic-co-glycolic acid), obtaining MGP nanoparticles, which are further covered by red blood cell (RBC) membrane. Because of the presence of proteins on RBC membranes, the nanoparticles could effectively avoid immune clearance in macrophages (Raw264.7) and significantly prolong their blood circulation time, thereby achieving higher accumulation at the tumor site. After that, the GOx in GMP@RBC could effectively catalyze the conversion of endogenous glucose to hydrogen peroxide (H2O2) in the presence of oxygen. The concomitant generation of H2O2 could efficiently trigger CO release to cause dysfunction of mitochondria and activate caspase, thereby resulting in apoptosis of the cancer cells. In addition, the depletion of intratumoral glucose could starve tumor cells by shutting down the energy supply. Altogether, the in vitro and in vivo studies of our synthesized biomimetic gas nanofactory exhibited an augmentative synergistic efficacy of CO gas therapy and energy starvation to inhibit tumor growth. It provides an attractive strategy to amplify CO generation for enhanced cancer therapy in an accurate and more efficient manner. STATEMENT OF SIGNIFICANCE: Carbon monoxide (CO) based gas therapy has emerged as an attractive therapeutic strategy for cancer therapy. In this study, we developed an erythrocyte membrane biomimetic gas nanofactory to amplify the in-situ generation of CO for combined cancer starvation and gas therapy. It is constructed by coating glucose oxidase (GOx) and CO donor-loaded nanoparticles with erythrocyte membrane. Due to the erythrocyte membrane, it can effectively prolong blood circulation time and achieve higher tumor accumulation. After accumulated in tumor, endogenous glucose can be effectively catalyzed to hydrogen peroxide, in-situ amplified CO release to induce the apoptosis of cancer cells. In addition, depleting glucose can also starve tumor cells by shutting down the energy supply. Overall, our biomimetic gas nanofactory exhibits an augmentative synergistic efficacy of CO gas therapy and starvation to increased tumor inhibition. It provide a novel strategy to deliver CO in an accurate and more efficient manner, promising for combined cancer therapy in future clinical application.

Therapeutic Implication of Carbon Monoxide in Drug Resistant Cancers

Harnessing Carbon Monoxide-Releasing Platforms for Cancer Therapy.

Thermal-Responsive Carbon Monoxide (CO) Delivery Expedites Metabolic Exhaustion of Cancer Cells toward Reversal of Chemotherapy Resistance

Gaseous signaling molecules and their application in resistant cancer treatment: from invisible to visible.

Carbon Monoxide (Co)-Strengthened Cooperative Bioreductive Anti-Tumor Therapy Via Mitochondrial Exhaustion and Hypoxia Induction

Abstract 4132: Low-dose carbon monoxide therapies suppress cancer metastasis

Toward Carbon Monoxide–Based Therapeutics: Critical Drug Delivery and Developability Issues

Low-dose carbon monoxide suppresses metastatic progression of disseminated cancer cells

Emerging Delivery Strategies of Carbon Monoxide for Therapeutic Applications: from CO Gas to CO Releasing Nanomaterials

Abstract A114: Low-dose carbon monoxide halts pancreatic cancer metastasis

Oral Carbon Monoxide Enhances Autophagy Modulation in Prostate, Pancreatic, and Lung Cancers

Photocatalyzing CO2 to CO for Enhanced Cancer Therapy

Controlled Release of Carbon Monoxide Based on Nanomaterials and Their Biomedical Applications

Exogenous carbon monoxide promotes GPX4-dependent ferroptosis through ROS/GSK3β axis in non-small cell lung cancer

Ultrasound-Mediated Antitumor Therapy Via Targeted Acoustic Release Carrier of Carbon Monoxide (TARC-CO).

Cancer cell membrane targeting and red light-triggered carbon monoxide (CO) release for enhanced chemotherapy

Carbon Monoxide Poisoning: From Microbes to Therapeutics

Starvation-amplified CO Generation for Enhanced Cancer Therapy Via an Erythrocyte Membrane-Biomimetic Gas Nanofactory.

Multifunctional Carbon Monoxide Nanogenerator As Immunogenic Cell Death Drugs with Enhanced Antitumor Immunity and Antimetastatic Effect.

Mitochondria Targeted Nanoparticles to Generate Oxygen and Responsive-Release of Carbon Monoxide for Enhanced Photogas Therapy of Cancer.

Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications